Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Epidemiology and risk factors for kidney cancer.Nat Rev Urol. 2010; 7: 245-257https://doi.org/10.1038/nrurol.2010.46
- Papillomatous tumor of the renal pelvis associated with similar tumors of the ureter and bladder. review of literature and report of two cases.J Urol. 1934; 31: 257-304https://doi.org/10.1016/S0022-5347(17)72407-X
- Recurrent carcinoma in the ureteric stump.Br J Surg. 1962; 50: 202-205https://doi.org/10.1002/bjs.18005022017
- European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update.Eur Urol. 2018; 73: 111-122https://doi.org/10.1016/j.eururo.2017.07.036
- Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.Cancer. 2014; 120: 1794-1799https://doi.org/10.1002/cncr.28655
- Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2017; 15: 804-834https://doi.org/10.6004/jnccn.2017.0100
- Imaging in suspected renal-cell carcinoma: systematic review.Clin Genitourin Cancer. 2019; 17: e345-e355https://doi.org/10.1016/j.clgc.2018.07.024
- CT appearance of transitional cell carcinoma of the renal pelvis: Part 2. Advanced-stage disease.AJR Am J Roentgenol. 1997; 169: 163-168https://doi.org/10.2214/ajr.169.1.9207518
- Centrally infiltrating renal masses on CT: differentiating intrarenal transitional cell carcinoma from centrally located renal cell carcinoma.AJR Am J Roentgenol. 2012; 198: 846-853https://doi.org/10.2214/AJR.11.7376
- Intrarenal urothelial cancers confused as infiltrative renal masses: Report of 22 cases and literature review.Oncol Lett. 2018; 16: 1912-1916https://doi.org/10.3892/ol.2018.8867
National Cancer Database. Available at: https://www.facs.org/quality-programs/cancer/ncdb. Accessed September 1, 2019.
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.J Clin Epidemiol. 1992; 45: 613-619https://doi.org/10.1016/0895-4356(92)90133-8
- The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments.Stat Med. 2014; 33: 1242-1258https://doi.org/10.1002/sim.5984
- Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study.Eur Urol. 2010; 57: 956-962https://doi.org/10.1016/j.eururo.2009.12.001
- Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma.Eur Urol. 2014; 65: 210-217https://doi.org/10.1016/j.eururo.2012.04.052
- A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma.Urol. 2010; 75: 118-124https://doi.org/10.1016/j.urology.2009.07.1296
- Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy.Eur Urol. 2010; 58: 581-587https://doi.org/10.1016/j.eururo.2010.06.029
- Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.BJU Int. 2013; 112: 453-461https://doi.org/10.1111/j.1464-410X.2012.11649.x
- Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the eau non-muscle invasive bladder cancer guidelines panel.Eur Urol. 2016; 70: 1052-1068https://doi.org/10.1016/j.eururo.2016.07.014
- Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients.BJU Int. 2012; 110: 1618-1626https://doi.org/10.1111/j.1464-410X.2012.11066.x
- The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy.Eur Urol. 2012; 61: 245-253https://doi.org/10.1016/j.eururo.2011.09.017
- Racial variation in the quality of surgical care for bladder cancer.Cancer. 2014; 120: 1018-1025https://doi.org/10.1002/cncr.28520
- Racial/ethnic disparities in perioperative outcomes of major procedures: results from the national surgical quality improvement program.Ann Surg. 2015; 262: 955-964https://doi.org/10.1097/SLA.0000000000001078
- Impact of surgical volume on mortality and length of stay after nephrectomy.Urol. 2004; 63: 862-867https://doi.org/10.1016/j.urology.2003.11.037
- The impact of provider volume on outcomes from urological cancer therapy.J Urol. 2005; 174: 432-438https://doi.org/10.1097/01.ju.0000165340.53381.48
- Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.BJU Int. 2012; 109: 77-82https://doi.org/10.1111/j.1464-410X.2011.10288.x
- Safety and diagnostic accuracy of percutaneous biopsy in upper tract urothelial carcinoma.BJU Int. 2015; 115: 625-632https://doi.org/10.1111/bju.12824
- Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma.BJU Int. 2011; 108: 701-705https://doi.org/10.1111/j.1464-410X.2010.09899.x
- Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival.Am J. Surg Pathol. 2000; 24: 980-987https://doi.org/10.1097/00000478-200007000-00009
- Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications forstudies that use the National Cancer Data Base.J Clin Oncol. 2009; 27: 4177-4181https://doi.org/10.1200/JCO.2008.21.7018
Conflict Of Interest: No conflict.
Funding Support: JS and DS are supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust. JS is supported by Damon Runyon Cancer Research Foundation physician scientist training award. XM is partially reported by the following grant: Clinical and Translational Science Center at Weill Cornell Medicine (1-UL1-TR002384-01).